Catheter Precision, Inc. (NYSE:VTAK) shares cleared breakeven Thursday. As the U.S.-based innovative medical device company focused on electrophysiology products today announced it has received its first purchase order for LockeT from the New York City area.
As previously announced, the company has recently expanded their US sales and clinical team in preparation for the national product launch of LockeT which includes the NYC region.
The most recent purchase order comes from Montefiore Medical Center located in the Bronx. Montefiore is a premiere academic medical center and the primary teaching hospital of the Albert Einstein College of Medicine in New York City. MMC is a part of the Montefiore Einstein health network that has over 300 locations including 13 hospitals, and it is estimated that Montefiore Medical Center performs over 1,000 electrophysiology and cardiac rhythm procedures each year.
Ronald Bowe, Area Sales Director - Eastern U.S. stated, "We are both honored and thrilled to undergo a new venture with Montefiore Health System, one of New York's premier academic health systems. Together we aim to have continued positive impacts on the many patients they treat annually, with the incorporation of our new LockeT device."
VTAK shares grew two cents, or 4.1%, to begin the day at 50 cents.
Related Stories
